Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant

Alimera Sciences (NSDQ:ALIM) said today that it inked an exclusive distribution deal with Spain-based Brill Pharma for its Iluvien sustained-release intravitreal implant.

According to the agreement, Brill Pharma will promote, market and commercialize the diabetic macular edema implant in Spain. It will also negotiate with the Spanish Ministry of Health on the implant’s public price and the appropriate net price for reimbursement within the Spanish National Health System.

Get the full story at our sister site, Drug Delivery Business News.

The post Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant appeared first on MassDevice.

from MassDevice http://ift.tt/2mj9pCI